This article was originally published in The Tan Sheet
FDA's Dermatologic Drugs and Anti-Infective Drugs Advisory Committees are scheduled to meet jointly on Nov. 16 to examine the potential for the development of antibiotic resistance if topical erythromycin were to be made available OTC for the treatment of acne. Originally scheduled for Sept. 23, the meeting was postponed to allow more time to find speakers, according to FDA
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC